FDA responds to some unacceptable structure/function claims with "courtesy" letters.
This article was originally published in The Tan Sheet
STRUCTURE/FUNCTION NOTIFICATIONS HAVE GENERATED FDA "COURTESY" LETTERS in "a couple of cases" to manufacturers registering structure/function claims that were "treatment claims for a disease condition," FDA Office of Special Nutritionals Director Elizabeth Yetley, PhD, told the Commission on Dietary Supplement Labels on Feb. 16. Yetley spoke at the commission's inaugural meeting in Washington, D.C.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC